Posterior Segment Age-related Macular Degeneration macular degeneration, Ophthalmology, 2001;108:1893–900.
10. Knudtson MD, Klein BE, Klein R, et al., Age-related eye disease, quality of life,and functional activity, Arch Ophthalmol, 2005;123:807–14.
11. La Cour, M, Kiilgaard JF, et al., Age Related Macular Degeneration: epidemiology and optimal treatment, Drugs Aging, 2002;19:101–33.
12. Cong R, Zhou B, Sun Q, et al., Smoking and the risk of age- related macular degeneration: a meta-analysis, Ann Epidemiol, 2008;18:647–56.
13. Age-Related Eye Disease Study Research Group, Risk factors associated with age-related macular degeneration. A case- control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3, Ophthalmology, 2000;107:2224–32.
14. Ikram MK, van Leeuwen R, Vingerling JR, et al. Relationship between refraction and prevalent as well as incident age-related maculopathy: the Rotterdam Study, Invest Ophthalmol Vis Sci, 2003;44:3778–82.
15. Hogg RE, Woodside JV, Gilchrist SE, et al., Cardiovascular disease and hypertension are strong risk factors for choroidal neovascularization, Ophthalmology, 2008;115:1046–52.e2.
16. Vingerling JR, Hofman A, Grobbee DE, et al., Age-related macular degeneration and smoking: the Rotterdam Study, Arch Ophthalmol, 1996;114:1193–6.
17. Clemons TE, Milton RC, Klein R, et al., Age-Related Eye Disease Study Research Group. Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age- Related Eye Disease Study (AREDS) AREDS report number 19, Ophthalmology, 2005;112(4):533–9.
18. Klein R, Klein BE, Tomany SC, et al., The association of cardiovascular disease with the long-term incidence of age- related maculopathy: the Beaver Dam Eye Study, Ophthalmology, 2003;110:1273–80.
19. van Leeuwen R, Ikram MK, Vingerling JR, et al., Blood pressure, atherosclerosis, and the incidence of age-related maculopathy: the Rotterdam Study, Invest Ophthalmol Vis Sci, 2003;44:3771–7.
20. Ambati J, Ambati BK, Yoo SH, et al., Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies, Survof Ophthalmol, 2003;48:257–93.
21. Holz FG, Pauleikhoff D, Klein R, et al., Pathogenesis of lesions in late age-related macular disease, Amer J Ophthalmol, 2004;137:504–10.
22. Zarbin MA, Current concepts in the pathogenesis of age-related macular degeneration, Arch Ophthalmol, 2004;122:598–614.
23. Gass JD, Drusen and disciform macular detachment and degeneration, Arch Ophthalmol, 1973;90:206–17.
24. Bird AC, Bressler NM, Bressler SB, et al., An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group, Surv Ophthalmol, 1995;39:367–74.
25. Green WR, Enger C, Age-related macular degeneration histopathologic studies. The 1992 Lorenz E. Zimmerman Lecture, Ophthalmology, 1993;100:1519–35.
26. Bressler NM, Silva JC, Bressler SB, et al., Clinicopathologic correlation of drusen and retinal pigment epithelial abnormalities in age-related macular degeneration, Retina, 1994;14:130–42.
27. Shelley EJ, Madigan MC, Natoli R, et al., Cone degeneration in aging and age-related macular degeneration, Arch Ophthalmol, 2009;127:483–92.
28. Green WR, Key SN, Senile macular degeneration: a histopathologic study, Trans Am Ophthalmol Soc, 1977;75:180–254.
29. Maguire MG, Bressler SB, Bressler NM, et al., Macular Photocoagulation Study Group: relationship of drusen and abnormalities of the retinal pigment epithelium to the prognosis of neovascular macular degeneration, Arch Ophthalmol, 1990;108:1442–7.
30. Zhang SX, Ma JX, Ocular neovascularization: implication of endogenous angiogenic inhibitors and potential therapy, Prog Retin Eye Res, 2007;26:1–37.
31. Dorrell M, Uusitalo-Jarvinen H, Aguilar E, et al., Ocular neovascularization: basic mechanisms and therapeutic advances, Surv Ophthalmol, 2007;52(Suppl. 1):S3–19.
32. Campochiaro PA, Ocular neovascularization and excessive vascular permeability, Expert Opin Biol Ther, 2004;4:1395–402.
33. Connolly DT, Heuvelman DM, Nelson R, et al., Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis, J Clin Invest, 1989;84:1470–8.
34. Iriyama A, Inoue Y, Takahashi H, et al., A2E, a component of lipofuscin, is pro-angiogenic in vivo, J Cellular Phys, 2009;220:469–75.
35. Stone EM, Braun TA, Russell SR, et al., Missense variations in the fibulin 5 gene and age-related macular degeneration, N Eng J Med, 2004;351:346–53.
36. Fisher SA, Abecasis GR, Yashar BM, et al., Meta-analysis of genome scans of age-related macular degeneration, Hum Mol Genet, 2005;14:2257–64.
37. Abecasis GR, Yashar BM, Zhao Y, et al., Age-related macular degeneration: a high-resolution genome scan for susceptibility loci in a population enriched for late-stage disease, Amer J Hum Genet, 2004;74:482–94.
38. Haddad S, Chen CA, Santangelo SL, et al., The genetics of age- related macular degeneration: a review of progress to date, Surv Ophthalmol, 2006;51:316–63.
39. Klein RJ, Zeiss C, Chew EJ, et al., Complement factor H polymorphism in Age-related Macular Degeneration, Science, 2005;308:385–9.
40. Zareparsi S, Branham KE, Li M, et al., Strong association of the Y402H variant in complement factor H at 1q32 with susceptibility to age-related macular degeneration, Am J Hum Genet, 2005;77:149–53.
41. Despriet DD, Klaver CC, Witteman JC, et al., Complement factor H polymorphism, complement activators, and risk of age- related macular degeneration, JAMA, 2006;296:301–9.
42. Rivera A, Fisher SA, Fritsche LG, et al., Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk, Hum Molec Genet, 2005;14:3227–36.
43. Gold B, Merriam JE, Zernant J, et al., Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration, Nat Genet, 2006;38:458–62.
44. Age related Eye Disease study Group, A randomized, placebo controlled, clinical trial of high dose supplementation with vitamins C and E, beta carotene, and zinc for age related macular degeneration and vision loss. AREDS report 8, Arch Ophthalmol, 2001;119:1417–36.
45. Ferris FL, Davis MD, Clemons TE, et al., Age Related Eye Disease Study Research Group, A simplified severity scale for age related macular degeneration: AREDS report 18, Arch Ophthalmol, 2005;123:1570–4.
46. Macular Photocoagulation Study Group. Argon Laser Photocoagulation for neovascular maculopathy: five year results form randomized clinical trials, Arch Ophthalmol,
1991;109:1109–14.
47. Treatment of Age Related Macular Degeneration with Photodynamic therapy (TAP) study Group, Photodynamic therapy of sub-foveal choroidal neovascularization Age Related Macular Degeneration with Verteporfin: two year results of 2 randomized clinical trials. TAP report 2, Arch Ophthalmol, 2001;119:198–207.
48. Verteporfin Photodynamic Therapy (VIP) Study Group, Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—Verteportin in Photodynamic Therapy Report 2, Am J Ophthalmol, 2001;131:541–60.
49. Gragoudas ES, Adamis AP, Cunningham ET, et al., VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for Neovascular age related macular Degeneration, N Engl J Med, 2004;351:2805–16.
50. Rosenfeld PJ, Brown DM, Heier JS, et al., Ranibizumab for neovascular age related macular degeneration (2 year results from the MARINA study), N Engl J Med, 2006;355:1419–31.
51. Brown DM, Kaiser PK, Michels M, et al., ANCHOR Study Group. Ranibizumab vs. Verteporfin for neovascular age related macular degeneration. (1 year results of the ANCHOR study), N Engl J Med, 2006;355:1432–44.
52. Brown DM, Michels M, Kaiser PK, et al., Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study, Ophthalmology, 2009;116:57–65.
53. Rosenfeld PJ, Moshfeghi AA, Puliafito CA, Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration, Ophthalmic Surg Lasers Imaging, 2005;36:331–5.
54. Schouten JS, La Heij EC, Webers CA, et al., A systematic review on the effect of bevacizumab in exudative age-related macular degeneration, Graefes Arch Clin Exp Ophthalmol, 2009;247:1–11.
55. Ciulla TA, Rosenfeld PJ, Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration, Curr Opin Ophthalmol, 2009;20:158–65.
56. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al., Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES), Graefes Arch Clin Exp Ophthalmol, 2008;246:81–7.
57. Fung AE, Rosenfeld PJ, Reichel E, The international intravitreal bevacizumab safety survey: using the Internet to assess drug safety worldwide, Br J Ophthalmol, 2007;90:1344–9.
58. Fung AE, Lalwani GA, Rosenfeld PJ, et al., An optical coherence tomography guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration, Am J Ophthalmol, 2007;143:566–83.
59. Regillo CD, Brown DM, Abraham P, et al., Randomized, double-masked, sham controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1, Am J Ophthalmol, 2008;145:239–48.
60. Ruiz-Moreno JM, Montero JA, Barile S, Zarbin MA, Photodynamic therapy and high-dose intravitreal triamcinolone to treat exudative age-related macular degeneration: 1-year outcome, Retina, 2006;26:602–12.
61. Ergun E, Maar N, Ansari-Shahrezaei S, et al., Photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide in the treatment of neovascular age-related macular degeneration, Am J Ophthalmol, 2006;142:10–6.
100
US OPHTHALMIC REVIEW
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116